Table 1 Relationship between CASC18 expression and clinicopathologic characteristics of TSCC patients
Clinical information | CASC18 (n = 34) | p-value | |
|---|---|---|---|
Low expression | High expression | ||
Age at diagnosis (year) | Â | Â | 1.000 |
 < 51 | 7 (41.2 %) | 10 (58.8 %) |  |
 ≥ 52 | 10 (58.8 %) | 7 (41.2 %) |  |
Sex | Â | Â | 0.493 |
 Female | 4 (23.5 %) | 4 (23.5 %) |  |
 Male | 13 (76.5 %) | 13 (76.5 %) |  |
Smoking | Â | Â | 0.303 |
 No | 11 (64.7 %) | 7 (41.2 %) |  |
 Yes | 6 (35.3 %) | 10 (58.8 %) |  |
Clinical T stage | Â | Â | 0.224 |
 T1 | 7 (41.2 %) | 3 (17.6 %) |  |
 T2 | 10 ( 58.8 %) | 13 (76.5 %) |  |
 T3 | 0 (0.0 %) | 1 (5.9 %) |  |
Pathologic T stage | Â | Â | 0.338 |
 T1 | 4 (23.5 %) | 1 (5.9 %) |  |
 T2 | 11 (64.7 %) | 13 (76.5 %) |  |
 T3 | 2 (11.8 %) | 3 (17.6 %) |  |
Pathologic N stage | Â | Â | 0.006 |
 N1 | 14 (82.4 %) | 5 (29.4 %) |  |
 N2 | 1 (5.9 %) | 8 (47.1 %) |  |
 N3 | 2 (11.8 %) | 4 (23.5 %) |  |
OLNM | Â | Â | 0.006 |
 No | 14 (82.4 %) | 5 (29.4 %) |  |
 Yes | 3 (17.6 %) | 12 (70.6 %) |  |